迪希德罗米瑞通过抑制尿酸再吸收来改善高尿血症
Ze-Rui Sun1,2,3, Hui-Zhen Peng4, Mao-Si Fan2
1College of Resources, Environment and Chemistry, Chuxiong Normal University, Chuxiong, China.
Journal of the science of food and agriculture
|April 9, 2025
概括
迪米瑞 (DMY) 通过抑制桑丁氧化酶和改变尿酸转运体表达来降低尿酸水平. 这种天然化合物还可以缓解损伤和与高尿血症相关的炎症.
科学领域:
- 生物化学 生化学
- 药理学 药理学是指药理学的学科.
- 自然产品 自然产品
背景情况:
- 超尿血症 (HUA) 是一种普遍的慢性疾病,与纯素代谢异常有关.
- 作为一种天然的黄类化合物,二米瑞 (DMY) 已表现出各种生物特性.
- DMY的抗HUA作用在很大程度上仍未被探索.
研究的目的:
- 调查DMY对高尿素血症 (HUA) 的调节作用.
- 探索DMY在管理HUA及其并发症方面的潜在机制.
主要方法:
- 使用人类肝细胞菌株和管状上皮细胞进行体外研究.
- 在体内研究涉及高尿素性 (HUA) 鼠标模型.
- 对关键酶,载体和炎症标记物的分析 (XOD,UA,ABCG2,URAT1,GLUT9,NLRP3炎症体).
主要成果:
- 在体外和体内,DMY显著降低了尿酸 (UA) 合成和丁氧化酶 (XOD) 表达.
- DMY调节的尿糖蛋白 (ABCG2) 和再吸收 (URAT1,GLUT9) 蛋白质,促进UA的分泌.
- 通过抑制NLRP3炎症酶激活,DMY改善了HUA诱导的损伤和脚.
结论:
- DMY在管理实验性高尿血症 (HUA) 中显示出显著的潜力.
- DMY通过多种机制发挥其抗HUA作用,包括XOD抑制和尿酸转运体的调制.
- DMY有效地减少了与HUA相关的炎症,表明了治疗价值.
更多相关视频
10:25Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology
Published on: November 22, 2024
208
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
473
相关概念视频
01:16Antihypertensive Drugs: Action of Diuretics
590
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
590
01:15Antihypertensive Drugs: Thiazide-Class Diuretics
467
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
467
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
130
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
130
01:25Antihypertensive Drugs: Direct Renin Inhibitors
458
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
458
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
478
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
478
01:22Drug Elimination by Renal Route: Tubular Reabsorption
3.1K
During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. However, the majority of drugs are either weak acids or weak bases, and their ionization level is dependent on pH. By altering the pH of urine, the...
3.1K